Indanidin
| |
| Nazivi | |
|---|---|
| Preferisani IUPAC naziv
N-(4,5-Dihidro-1H-imidazol-2-il)-2-metil-4-indazolamin | |
| Sistemski IUPAC naziv
N-(4,5-Dihidro-1H-imidazol-2-il)-2-metil-2H-indazol-4-amin | |
| Drugi nazivi
N-(4,5-Dihidro-1H-imidazol-2-il)-2-metilindazol-4-amin
| |
| Identifikacija | |
3D model (Jmol)
|
|
| ChEBI | |
| ChemSpider | |
| MeSH | Indanidine |
| |
| Svojstva | |
| C11H13N5 | |
| Molarna masa | 215,25442 |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
| Reference infokutije | |
Indanidin je alfa-adrenergički agonist.[3]
Reference[уреди | уреди извор]
- ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
- ^ Van der Graaf PH, Shankley NP, Black JW (1996). „Analysis of the action of idazoxan calls into question the reliability of the rat isolated small mesenteric artery assay as a predictor for alpha 1-adrenoceptor-mediated pressor activity”. Naunyn Schmiedebergs Arch Pharmacol. 354: 389—92.
